Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
M05BX07
|
| gptkbp:brand |
gptkb:Crysvita
|
| gptkbp:CASNumber |
1610762-09-8
|
| gptkbp:developer |
gptkb:Kyowa_Kirin
gptkb:Ultragenyx_Pharmaceutical |
| https://www.w3.org/2000/01/rdf-schema#label |
burosumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
gptkb:FGF23
|
| gptkbp:UNII |
6Y7T4T2UQ9
|
| gptkbp:usedFor |
gptkb:X-linked_hypophosphatemia
gptkb:tumor-induced_osteomalacia |
| gptkbp:bfsParent |
gptkb:Crysvita
|
| gptkbp:bfsLayer |
8
|